Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and well-tolerated.
New Genesis is the ultimate PSO2 experience in which the time-tested elements are kept intact, while the game design, ...
Superiority of deucravacitinib was demonstrated on both co-primary endpoints and multiple key secondary endpoints in the POETYK PSO-1 trial The overall safety profile of deucravacitinib in this study ...
Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...
The approval was based on data from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials in adults with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) has approved Sotyktu ™ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results